Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro

Journal of Cellular Physiology

Volumn 226, Issue 12, 2011, Pages 3233-3241

  Cantley, M D ^a   Fairlie, D P ^b   Bartold, P M ^a   Rainsford, K D ^c   Le, G T ^b   Lucke, A J ^b   Holding, C A ^a   Haynes, D R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BETA INTERFERON; ENTINOSTAT; ENZYME INHIBITOR; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; N8 HYDROXY 2 (1H INDOLE 2 CARBOXAMIDO) N1 (QUINOLIN 8 YL)OCTANEDIAMIDE; OSTEOCLAST ASSOCIATED RECEPTOR; RECEPTOR; TERT BUTYL 1 (CYCLOPENTYLAMINO) 7 MERCAPTO 1 OXOHEPTAN 2 YL CARBAMATE; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DENTIN; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACID PHOSPHATASE; BENZAMIDES; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; DENTIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INTERFERON-BETA; ISOENZYMES; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-FOS; PYRIDINES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CALCITONIN; RECEPTORS, CELL SURFACE; RNA, MESSENGER; TIME FACTORS; TNF RECEPTOR-ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTORS;

EID: 80053165908     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22684     Document Type: Article

References (58)

1. Asagiri M, Takayanagi H. 2007. The molecular understanding of osteoclast differentiation. Bone 40: 251-264.
2. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. 2001. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16: 348-360.
3. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM. 2004. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059-1066.
4. Bhavsar P, Ahmad T, Adcock IM. 2008. The role of histone deacetylases in asthma and allergic diseases. J Allergy Clin Immunol 121: 580-584.
5. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423: 337-342.
6. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM. 2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99: 11700-11705.
7. Cantley M, Smith M, Haynes D. 2009. Pathogenic bone loss in rheumatoid arthritis: Mechanisms and therapeutic approaches. Int J Clin Rheumatol 4: 561-582.
8. Chen LF, Greene WC. 2004. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 5: 392-401.
9. Chung YL, Lee MY, Wang AJ, Yao LF. 2003. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8: 707-717.
10. Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, Ahern MJ, Haynes D. 2003a. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 38: 380-387.
11. Crotti TN, Ahern MJ, Lange K, Weedon H, Coleman M, Roberts-Thomson PJ, Haynes DR, Smith MD. 2003b. Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: Quantification using color video image analysis. J Rheumatol 30: 2319-2324.
12. De ruijter A, Van Gennio A, Caron H, Kemp S, Van Kuilenburg A. 2002. Histone deacetylases: Characterization of the classical HDAC family. Biochem J 370: 737-749.
13. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. 2003. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 370: 737-749.
14. Dokmanovic M, Marks PA. 2005. Prospects: Histone deacetylase inhibitors. J Cell Biochem 96: 293-304.
15. Duong V, Bret C, Altucci L, Mai A, Duraffourd C, Loubersac J, Harmand PO, Bonnet S, Valente S, Maudelonde T, Cavailles V, Boulle N. 2008. Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res 6: 1908-1919.
16. Duvic M, Vu J. 2007. Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16: 1111-1120.
17. Franssen ME, Zeeuwen PL, Vierwinden G, van de Kerkhof PC, Schalkwijk J, van Erp PE. 2005. Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. J Invest Dermatol 124: 373-383.
18. Glozak MA, Sengupta N, Zhang X, Seto E. 2005. Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23.
19. Granfar RM, Day CJ, Kim MS, Morrison NA. 2005. Optimised real-time quantitative PCR assays for RANKL regulated genes. Mol Cell Probes 19: 119-126.
20. Grant S, Easley C, Kirkpatrick P. 2007. Vorinostat. Nat Rev Drug Discov 6: 21-22.
21. Gupta PK, Reid RC, Liu L, Lucke AJ, Broomfield SA, Andrews MR, Sweet MJ, Fairlie DP. 2010. Inhibitors Selective For HDAC6 in Enzymes and Cells. Bioorg Med Chem Lett 20: 7067-7070.
22. Haynes DR. 2006. Emerging and future therapies for the treatment of bone loss associated with chronic inflammation. Inflammopharmacology 14: 193-197.
23. Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA. 2004. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 279: 13984-13992.
24. Hofbauer LC, Heufelder AE. 2001. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79: 243-253.
25. Holding CA, Findlay DM, Stamenkov R, Neale SD, Lucas H, Dharmapatni AS, Callary SA, Shrestha KR, Atkins GJ, Howie DW, Haynes DR. 2006. The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 27: 5212-5219.
26. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M. 2003. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307: 720-728.
27. Huang L. 2006. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J Cell Physiol 209: 611-616.
28. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. 2006. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 66: 5409-5418.
29. Kahnberg P, Lucke AJ, Glenn MP, Boyle GM, Tyndall JD, Parsons PG, Fairlie DP. 2006. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. J Med Chem 49: 7611-7622.
30. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
31. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P. 2002. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99: 2995-3000.
32. Lerner UH. 2000. Osteoclast formation and resorption. Matrix Biol 19: 107-120.
33. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA. 2007. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22: 1832-1841.
34. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clement-Lacroix P. 2007. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150: 862-872.
35. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
36. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, Hisatake K, Nogi Y. 2004. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 279: 45969-45979.
37. Matsuo K, Irie N. 2008. Osteoclast-osteoblast communication. Arch Biochem Biophys 473: 201-209.
38. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. 2006. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821-831.
39. Monneret C. 2005. Histone deacetylase inhibitors. Eur J Med Chem 40: 1-13.
40. Nagy ZB, Gergely P, Donath J, Borgulya G, Csanad M, Poor G. 2008. Gene expression profiling in Paget's disease of bone: Upregulation of interferon signaling pathways in pagetic monocytes and lymphocytes. J Bone Miner Res 23: 253-259.
41. Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Ogawa K, Hotokebuchi T, Kohashi O, Kukita A. 2005. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 175: 5809-5816.
42. Perrone M. 2010. FDA clears Amgen's bone strengthening drug Prolia. BioScience Technology
43. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. 2003. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 101: 3451-3459.
44. Richon VM, O'Brien JP. 2002. Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 8: 662-664.
45. Rubin J, Greenfield E. 2005. Osteoclast: Origin and differentiation. Bone Resorption Volume II. Bone Biology Series Chapter 1. Felix Bronner MCF-CaJR, editor. London: Springer-Verlag.
46. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA. 2005a. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23: 3912-3922.
47. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA. 2005b. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23: 3912-3922.
48. Sharma SM, Bronisz A, Hu R, Patel K, Mansky KC, Sif S, Ostrowski MC. 2007. MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem 282: 15921-15929.
49. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, Mariko Y, Yamashita T, Nakanishi O. 1999. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42: 3001-3003.
50. Suzuki T, Kouketsu A, Itoh Y, Hisakawa S, Maeda S, Yoshida M, Nakagawa H, Miyata N. 2006. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J Med Chem 49: 4809-4812.
51. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. 2006. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281: 5612-5622.
52. Takayanagi H. 2007. The role of NFAT in osteoclast formation. Ann NY Acad Sci 1116: 227-237.
53. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901.
54. Trepel J, Birrer MJ. 2003. A link between histone deacetylase inhibitors and NF-kappaB signaling. Cell Cycle 2: 452-453.
55. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA. 2007. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 35: W71-W74.
56. Vernia P, Annese V, Bresci G, d'Albasio G, D'Inca R, Giaccari S, Ingrosso M, Mansi C, Riegler G, Valpiani D, Caprilli R. 2003. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: Results of a multicentre trial. Eur J Clin Invest 33: 244-248.
57. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-3602.
58. Yin L, Laevsky G, Giardina C. 2001. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 276: 44641-44646.